Skip to content

Transcranial stimulation in patients with early-stage cognitive impairments: Treatment efficacy and underlying mechanisms

Transcranial stimulation in patients with early-stage cognitive impairments: Treatment efficacy and underlying mechanisms

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
ChiCTR
Registry ID
ChiCTR1900024955
Enrollment
Unknown
Registered
2019-08-05
Start date
2019-11-18
Completion date
Unknown
Last updated
2026-06-01

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

stroke

Interventions

tDCS group 1:tDCS+cognitive training
tDCS group 2:tDCS+sham cognitive training
tDCS group 3:sham tDCS+cognitive training
tDCS group 4:sham tDCS+sham cognitive training
TMS group 1:TMS
TMS group 2:Sham TMS

Sponsors

Guangzhou First People's Hospital
Lead Sponsor

Eligibility

Sex/Gender
All
Age
55 Years to 80 Years

Inclusion criteria

Inclusion criteria: 1. Acute ischemic stroke patients; 2. Aged 55 to 80 years old; 3. Normal or corrected-to-normal vision and hearing; 4. Patients provides informed consent; 5. At least three days between the stroke and the starting of the study.

Exclusion criteria

Exclusion criteria: 1. Pre-stroke psychiatric or neurological disease by self-report (e.g., anxiety disorder, ADHD, Parkinson's disease, etc.); 2. History of diagnosed severe depression (diagnosed pre-stroke); 3. History of epilepsy (diagnosed pre-stoke); 4. Family history of epilepsy; 5. Fainting spells or syncope in the last three years pre-stroke; 6. Significant hearing loss, vision or motor impairment that would prevent them from performing the task; 7. Known to be pregnant; 8. Consuming medication affecting cortical excitability or recreational drugs; 9. Metal (except titanium) or electronic implants in the brain /skull (e.g., splinters, fragments, clips, cochlear implant, deep brain stimulation, medication pump); 10. Metal (except titanium) or any electronic device at other sites in your body, such as cardiac pacemaker or traumatic metallic residual fragments; 11. Skin problems such as dermatitis, psoriasis or eczema under the stimulation sites; 12. Brain stimulation in the past six months; 13. Undergone transcranial electric or magnetic stimulation in the past (more than 6 months) which resulted in adverse effects; 14. Skull fractures, significant skull defects, skull plates or large vessels occlusions in the site of electrode placement; 15. Seizure at the time of stroke or between the stroke and starting of the therapy; 16. Severe cognitive problem which affect the understanding of training task.

Design outcomes

Primary

MeasureTime frame
n-back level;

Secondary

MeasureTime frame
Accuracy of offline n-back task;digit span (Forward/Backward);Spatial Addition;Symbol span;Mood outcomes;Mental state;

Countries

China

Contacts

Public ContactJin Zhou

Guangzhou First People's Hospital

ghzj5354@163.com+86 137 1108 3105

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Jun 11, 2026